 
 
 
JAGSONPAL PHARMACEUTICALS LIMITED 
Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, 
Haryana (India) 
Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com 
CIN NO. L74899DL1978PLC009181 
Regd. Office: T-210 J, Shahpur Jat, New Delhi - 110049 (India) 
 
August 27, 2024 
The Department of Corporate Services- Listing 
BSE Ltd, 
Phiroze Jeejeebhoy Towers, 
Dalal Street 
Mumbai-400 001 
Scrip Code: 507789 
The Department of Corporate Services- Listing 
National Stock Exchange of India Ltd 
Exchange Plaza, C-1, Block G, 
Bandra Kurla Complex, 
Bandra (E) Mumbai – 400 051 
Symbol: JAGSNPHARM 
 
Subject: Business Responsibility and Sustainability Report for the financial year 2023-24 
 
Dear Sir/ Madam, 
 
Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations & Disclosure Requirements) 
Regulations 2015, please find enclosed the Business Responsibility and Sustainability Report 
(“BRSR”) for the financial year 2023-24 which forms an part of the Annual Report for the financial 
year 2023-24. 
We request you to take the above on record.  
Thanking you, 
For Jagsonpal Pharmaceuticals Limited 
 
 
 
Abhishek Joshi 
Company Secretary & Compliance Officer 
 
Encl.: A/a 
 
 
ABHISHE
K JOSHI
Digitally signed by 
ABHISHEK JOSHI 
Date: 2024.08.27 
18:45:08 +05'30'
Section A: General Disclosures
I. 	
Details of the listed entity
1.
Corporate Identity Number (CIN)
L74899DL1978PLC009181
2.
Name of company
Jagsonpal Pharmaceuticals Limited
3.
Year of incorporation
1978
4.
Registered office address
T-210 J, Shahpur Jat, New Delhi – 110 049 (India)
5.
Corporate office address
Plot No. 412-415
Nimai Tower, 3rd Floor
Phase-IV, Udyog Vihar, Sector 18
Gurugram -122 015, Haryana (India)
6.
E-mail
cs@jagsonpal.com
7.
Telephone
+91 124 4406710
8.
Website
www.jagsonpal.com
9.
Financial year for which reporting is being done
April 1, 2023 – March 31, 2024
10.
Name of the stock exchange(s) where shares are listed
BSE Limited and National Stock Exchange of India 
Limited
11.
Paid-up capital (In ₹)
₹ 13,21,88,970/-
12.
Name and contact details (telephone, email address) 
of the person who may be contacted in case of any 
queries on the BRSR report
Name: Mr. Abhishek Joshi,  
Designation: Company Secretary,  
Telephone no.: +91 124 4406710
Email ID: cs@jagsonpal.com
13.
Reporting boundary
Standalone basis
14.
Name of assurance provider
NA
15.
Type of assurance obtained
NA
II.	
Products/services
16.	 Details of business activities (accounting for 90% of the turnover):
The company is engaged in the business of marketing and distribution of pharmaceutical formulations.
17.	 Products/Services sold by the entity (accounting for 90% of the entity’s Turnover):
S. 
No. Product/Service
NIC Code
% of total turnover contributed
1.
Pharmaceutical formulations
21002
97%
III.	 Operations
18.	 Number of locations where plants and/or operations/offices of the entity are situated:
•	
Registered Office in New Delhi
•	
Corporate Office in Gurugram, Haryana and Mumbai, Maharashtra
•	
Warehouse in Ghaziabad, Uttar Pradesh
Business Responsibility and Sustainability Report 
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
64
	
(B)	 Exports – The Company exports products to USA and South Korea. Exports contributes 3% of the total turnover of 
the company.
	
(C)	 Customers – The customers are important stakeholders in our business. The Company’s customer base includes 
Health Care Professionals and Government Institutions.
19.	 Markets served by the entity
(A)	 No. of locations
NATIONAL
INTERNATIONAL
(No. of States)
(No. of Countries)
29
2
IV.	 Employees
20.	 Details as at the end of Financial Year
	
a.	
Employees and workers (including differently abled):
S.
No. Particulars
Total (A)
Male
Female
No. (B)
% (B / A)
No. (C)
% (C / A)
Employees
1.
Permanent (D)
1025
1005
98%
20
2%
2.
Other than Permanent (E)
10
9
90%
1
10%
3.
Total employees (D + E)
1035
1014
98%
21
2%
Workers
1.
Permanent (F)
-
-
-
-
-
2.
Other than Permanent (G)
5
5
100%
-
-
3.
Total workers (F + G)
5
5
100%
-
-
	
b.	
Differently abled Employees and workers:
S.
No. Particulars
Total (A)
Male
Female
No. (B)
% (B / A)
No. (C)
% (C / A)
Employees
1.
Permanent (D)
0
0
0%
0
0%
2.
Other than Permanent (E)
0
0
0%
0
0%
3.
Total differently abled employees (D+E) 
0
0
0%
0
0%
Workers
1.
Permanent (F)
0
0
0%
0
0%
2.
Other than Permanent (G)
0
0
0%
0
0%
3.
Total differently abled workers (F+G) 
0
0
0%
0
0%
Business Responsibility and Sustainability Report  | Statutory Reports  ●
65
 
 
21.	 Participation/Inclusion/Representation of women
Total (A)
06
33%
02
0%
00
02
Board of Directors 
(including MD)
Key Managerial Personnel 
(Chief Financial Officer* 
and Company Secretary)
No. and percentage of Females
No. (B)
% (B / A)
*Mr. S.V. Subha Rao ceased to be Chief Financial Officer of the Company w.e.f February 02, 2024 and Mr. Ashish Lakhotia has been appointed 
as Chief Financial Officer of the Company w.e.f February 03, 2024
22.	 Turnover rate for permanent employees and workers
FY 2023-24
(Turnover rate in current 
FY) Resignations
FY 2022-23 (Turnover 
rate in previous FY) 
Resignations
FY 2021-22 (Turnover rate 
in the year prior to the 
previous FY) Resignations
Male
Female
Total
Male
Female
Total
Male
Female
Total
Permanent Employees
58%
1%
59%
49%
1%
50%
35%
1%
36%
Permanent Workers
-
-
-
-
-
-
-
-
-
V.	
Holding, Subsidiary and Associate Companies (including joint ventures)
23.	 (A) Names of holding/subsidiary/associate companies/joint ventures
S. 
No.
Name of the holding/
subsidiary/ associate 
companies/
joint ventures (A)
Indicate whether holding/ 
subsidiary/associate/
joint venture
% of shares held by 
listed entity
Does the entity indicated at column 
A, participate in the Business 
Responsibility initiatives of the listed 
entity? (Yes/No)
As on March 31, 2024, Company does not have any Subsidiary, Associate and Joint Venture Company.
VI.	 CSR Details
24.	  i.	
Whether CSR is applicable as per Section 135 of Companies Act, 2013: Yes
	
ii.	
Turnover (in Millions) – ` 2,087.02
	
iii.	
Net worth (in Millions) – ` 1,874.02
VII.	 Transparency and Disclosures Compliances
25.	 Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on 
Responsible Business Conduct:
Stakeholder group 
from whom complaint 
is received
Grievance Redressal 
Mechanism in	Place 
(Yes/No)
(If Yes, then provide 
web-link for grievance 
redress policy)
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Communities
info@jagsonpal.com 
0
0
NA
0
0
NA
Investors (other than 
shareholders)
cs@jagsonpal.com
0
0
NA
0
0
NA
Shareholders
cs@jagsonpal.com
4
0
NA
2
0
NA
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
66
Stakeholder group 
from whom complaint 
is received
Grievance Redressal 
Mechanism in	Place 
(Yes/No)
(If Yes, then provide 
web-link for grievance 
redress policy)
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution 
at close of 
the year
Remarks
Employees and 
workers
info@jagsonpal.com
0
0
NA
0
0
NA
Customers
customercare@
jagsonpal.com
Consumers can 
raise a concern via 
post, via given email 
(customercare@
jagsonpal.com) 
and reach out to us 
directly via telephone 
(+91-124 4406710). 
Also the consumer 
can reach out to the 
Company through 
official communication 
channel available on 
our website
www.jagsonpal.com
8
0
NA
18
0
NA
Value Chain Partners
-
-
-
-
-
-
-
Other (please specify)
-
0
0
NA
0
0
NA
26.	 Overview of the entity’s material responsible business conduct issues
The material issues are risks to the Company but at the same time, if acted upon proactively, could provide significant 
opportunities for the company over its competitors.
Some material issues identified are as follows –
ESG Dimension
Material issues
Indicate 
whether 
risk or 
opportunity
Management approach
Financial 
implications of the 
risk or opportunity 
(Indicate positive 
or negative 
implications)
Business Ethics
Prevention of 
bribery and 
corruption
Risk
The Company is committed to preventing 
bribery and corruption. It fosters a transparent 
work environment where management and key 
personnel are readily accessible. To support this, 
policies such as the Whistleblower Policy have 
been implemented. Both external and internal 
stakeholders are encouraged to report any 
malpractices observed within the Company.
Negative
Data 
protection
and 
Cybersecurity
Risk
The Company has a robust data protection 
system in place, including a cloud backup facility. 
It follows the 3-2-1 Data Protection and Recovery 
Plan, which involves maintaining three copies of 
server data on two different types of media, with 
one air-gapped copy stored offsite.
Negative
Business Responsibility and Sustainability Report  | Statutory Reports  ●
67
Section B: Management and Process Disclosures
The section aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting 
the National Guidelines on Responsible Business Conduct (NGRBC) Principles and Core Elements. The NGRBC, as prescribed 
by the Ministry of Corporate Affairs, advocates nine principles referred as P1-P9 as given below:
a)	
Principle 1 (P1): 	
Businesses should conduct and govern themselves with integrity and in a manner that is Ethical, 
Transparent and Accountable.
b)	
Principle 2 (P2): 	 Businesses should provide goods and services in a manner that is sustainable and safe.
c)	
Principle 3 (P3): 	 Businesses should respect and promote the well-being of all employees, including those in their 
value chains.
d)	
Principle 4 (P4): 	 Businesses should respect the interests of and be responsive to all its stakeholders.
e)	
Principle 5 (P5): 	 Businesses should respect and promote human rights.
f)	
Principle 6 (P6): 	 Businesses should respect and make efforts to protect and restore the environment.
g)	
Principle 7 (P7): 	 Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that 
is responsible and transparent.
h)	
Principle 8 (P8): 	 Businesses should promote inclusive growth and equitable development.
i)	
Principle 9 (P9): 	 Businesses should engage with and provide value to their consumers in a responsible manner.
ESG Dimension
Material issues
Indicate 
whether 
risk or 
opportunity
Management approach
Financial 
implications of the 
risk or opportunity 
(Indicate positive 
or negative 
implications)
Human 
Resources
Occupational 
Health and 
Safety
Risk
The Company believes that a safe and healthy 
work environment for employees is essential to 
the growth of any organisation. Furthermore, it 
has appropriate insurance coverage to manage 
any incidents of illness, injury, or fatalities.
Negative
Training and 
Development
Opportunity Employees are encouraged to pursue in-house 
career 
development 
opportunities. 
Training 
programs, 
effective 
communication, 
and 
leadership development activities for growth of 
employees are the foundation of the organisation.
Positive 
Supply Chain
Supply Chain 
Management
Risk
The Company has a network of suppliers and 
channel partners who may be exposed to 
disruption risk. During the onboarding process 
for suppliers, channel partners, and third-party 
contract manufacturers, mechanisms are in place 
to conduct detailed assessments of them to 
ensure regulatory compliance and to reduce the 
probability and impact of risk on Company.
Negative
Social 
outcomes
Product 
Quality
and Patient 
Safety
Risk
The Company understands its responsibility 
to provide quality products to consumers. The 
Quality assurance team proactively reviews 
complaints and works towards resolving them 
effectively.
Negative

Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
68
1.	
Principle-wise Policies and Procedures
Principle
Particulars
Policies
P1
Ethics and 
Transparency
The Company has formulated the following policies to promote an ethical and transparent 
culture and to express zero tolerance for unethical behavior: Whistleblower Policy, Code 
of Conduct, Policy for Determination of Materiality of Events, Policy on Related Party 
Transactions, Code of Practices and Procedures for Fair Disclosure of Unpublished Price 
Sensitive Information, and Information Security Policy.
P2
Sustainable and Safe 
Product
The Company strives to achieve sustainability by balancing resource utilisation with social, 
environmental, and economic considerations. It has established adequate procedures to 
ensure the delivery of high-quality products to its users.
P3
Well-being of 
Employees
The Company recognises human capital as an integral pillar and takes adequate steps to 
promote the individual goals of its human assets alongside the Company’s goals. Policies 
and procedures are in place for employee welfare, guiding the organisation to maintain a 
healthy work environment and establish systems for rewarding and recognising deserving 
individuals.
P4
Responsive to 
Stakeholders
The Company aims to create long-term value for its stakeholders. It has established 
proper procedures to protect and promote the interests of both its internal and external 
stakeholders.
P5
Respect for Human 
Rights
The Company considers respecting human rights as its fundamental responsibility. This 
commitment not only strengthens stakeholder trust but also promotes a healthy and safe 
working environment for employees, facilitating efficient growth for the Company.
P6
Environment 
Protection
Promoting its goal of sustainability, the Company strives to take adequate measures for 
energy conservation while efficiently employing technology. It regularly takes steps to 
raise awareness among employees about the importance of sustainability.
P7
Public Policy 
Advocacy
The Company has consistently focused on its policies and advocated for changes to 
existing policy frameworks whenever necessary.
P8
Inclusive Growth
As a member of society, the Company acknowledges its responsibility to contribute 
positively. To contribute to the growth of society especially weaker sections of the society, 
it focuses on education & livelihood and health & sanitation, as part of its CSR initiatives.
P9
Concern and Value 
for Customers
The Company acknowledges the vital role and significance of its product users. It aims 
to deliver high-standard products at affordable prices, contributing to the creation of a 
healthy nation. Procedures for redressal of consumer grievances and receipt of feedback 
have been implemented. Additionally, policies regarding Information Security and 
Cybersecurity ensure the confidentiality of data and information held by the Company.
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
Policy and management process
1.	
a.	
Whether your entity’s policy/policies cover each 
principle and its core elements of the NGRBCs. 
(Yes/No)
Y
Y
Y
Y
Y
Y
Y
Y
Y
	
b.	
Has the policy been approved by the board 
(Yes/No)
Yes, as applicable
	
c.	
Web Link of the policies, if available
https://www.jagsonpal.com/investor-relations
2.	
Whether the entity has translated the policy into 
procedure. (yes/No)
Yes (as applicable)
3.	
Do the enlisted policies extend to your value chain 
partners? (Yes/No)
Yes (as applicable)
4.	
Name of the national and international codes/
certifications/labels/standards (e.g. SA 8000, OHSAS, 
ISO,BIS) adopted by your entity with defined 
timelines, if any
All the contract manufacturing units, manufacturing drug 
products for Jagsonpal, comply with the national standards i.e. 
Schedule-M as per the Drugs and Cosmetics act 1940.
5.	
Specific commitments, goals and targets set by the 
entity with defined timelines, if any
This is not applicable since the company doesn’t operate any 
manufacturing facility thereby limiting the ability to set goals 
and targets for third parties.
6.	
Performance of the entity against the specific 
commitments, goals and targets along-with reasons 
in case the same are not met
Not Applicable
Business Responsibility and Sustainability Report  | Statutory Reports  ●
69
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
Governance, leadership and oversight
7.	
Statement by director responsible for the business 
responsibility report, highlighting ESG related 
challenges, targets and achievements (listed entity 
has flexibility regarding the placement of this 
disclosure)
The company equally prioritizes sustainable business growth 
and has initiated structured CSR activities that align with its 
corporate strategy. The company is dedicated to making a 
significant impact in society by focusing on a defined set of 
activities and demonstrating commitment to women’s welfare, 
which is in line with the company’s area of operations.
8.	
Details of the highest authority responsible for 
implementation and oversight of the Business 
Responsibility policy (ies)
•	
Director Identification Number (DIN): 06805265
•	
Name: Mr. Manish Gupta
•	
Designation: Managing Director
9.	
Does the entity has a specified Committee of the 
Board/ Director responsible for decision making on 
sustainability related issues? (yes/No) If yes, provide 
details.
•	
Director Identification Number (DIN): 06805265
•	
Name: Mr. Manish Gupta
•	
Designation: Managing Director
10.	 Details of review of NGRBCs by the company
Subject for Review
Indicate whether review was undertaken by 
Director/Committee of the board/any other 
committee (P1 to P9 )
Frequency (Annually/Half-yearly/
quarterly/any other-please specify) 
(P1 to P9)
Performance against above 
policies and follow up action
The necessary adjustments to policies and 
procedures are implemented as required, 
and any instances of non-compliance are 
noted for further appropriate action.
Policies of the Company are 
reviewed on a periodic basis to 
align it with regulatory changes
Compliance with statutory 
requirements of relevance to the 
principles, and rectification of any 
non-compliances
The company has no reportable non-
compliances.
As and when necessary, in 
compliance with statutory 
requirements
11.
Has the entity carried out 
independent assessment/ 
evaluation of the working of its 
policies by an external agency? 
(Yes/No). If yes, provide name of 
the agency.
No
12.	  If answer to question (1) above is “no” i.e., not all principles are covered by a policy reason to be stated.
Questions
P1 to P9
The entity does not consider the principles material to its business (Yes/No)
Not Applicable
The entity is not at a stage where it is in a position to formulate and implement the policies on 
specified principles (Yes/No)
The entity does not have the financial or/human and technical resources available for the task 
(Yes/No)
It is planned to be done in the next financial year (Yes/No)
Any other reason (please specify)
Section-C: Principle – wise Performance Disclosure
A.	
Principle 1: Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, 
Transparent and Accountable.
The company has established a code of conduct to guide its ethical and transparent operations. Our defined organisational 
structure ensures clear accountability, reducing the risk of miscommunication.
We operate in the healthcare sector ensuring delivery of quality services at a reasonable price making it reachable for 
all sections of society. We endeavour to ensure compliance with all applicable laws, rules and regulations.
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
70
Essential Indicators
1.	
Percentage coverage by training and awareness programmes on any of the principles during the financial 
year:
All employees received training on how to conduct themselves as per their roles and responsibilities, during the 
Periodic Training, with 781 employees attending the Prevention of Sexual Harassment (POSH) training in 2023-24.
Segment
Total number of trainings and awareness programmes held, and 
Topics / Principles covered under the trainings
% of persons in 
respective category 
covered by the 
awareness programmes
Board of Directors 
& Key Managerial 
Personnel
After appointment of directors, the Company provides a 
comprehensive board induction kit which captures company-
specific information at a broad level. This is followed by 
management discussion. The Board of Directors submits a 
declaration for compliance with code of conduct on annual 
basis.
100%
Employees other than 
BOD and KMPs
Employees undergo various training programmes including 
prevention of sexual harassment, ethical business practices, 
prohibition of insider trading etc.
76%
Workers
Not Applicable, since the company is not involved in 
manufacturing.
-
2.	
Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in 
proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial 
institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the 
basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) 
Regulations, 2015 and as disclosed on the entity’s website):
Monetary
NGRBC 
Principle
Name of the regulatory 
enforcement agencies/
judicial institutions
Amount (in 
INR)
Brief of the case
Has an appeal 
been preferred?
(yes/No)
Penalty/Fine
P1 – Ethics and 
Transparency
Office of the Principal 
Commissioner of 
Customs
5,09,79,206/-
Levy of differential 
duty towards 
incorrect classification 
of goods imported
No
Settlement
Nil
Nil
Nil
Nil
Nil
Compounding 
Fee
Nil
Nil
Nil
Nil
Nil
Non-Monetary
Imprisonment
Nil
Nil
Nil
Nil
Nil
Punishment
Nil
Nil
Nil
Nil
Nil
3.	
Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where 
monetary or non-monetary action has been appealed.
Case Details
Name of the regulatory/enforcement agencies/judicial institutions
NA
-
4.	
Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if 
available, provide a web link to the policy.
The Company remains focused on maintaining a healthy and ethical culture within the organisation. We have 
formulated policies having zero-tolerance against bribery and corruption and established procedures prohibiting 
any kind of bribery and corruption. The Company has a Code of Conduct, Code of Practices and Procedures for Fair 
Disclosure of Unpublished Price Sensitive Information and policies like Whistle Blower Policy which are available at 
https://www.jagsonpal.com/investor-relations.
5.	
Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law 
enforcement agency for the charges of bribery/corruption.
There were no such instances for FY 2023-24 and 2022-23.
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Directors
0
0
KMPs
0
0
Employees
0
0
Workers
0
0
Business Responsibility and Sustainability Report  | Statutory Reports  ●
71
6.	
 Details of complaints regarding conflict of interest:
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Number
Remarks
Number
Remarks
Number of complaints received in relation to issues of 
conflict of interest of the board of directors
0
0
0
0
Number of complaints received in relation to issues of 
conflict of interest of the KMPs
0
0
0
0
7.	
Provide details of any corrective action taken or underway on issues related to fines / penalties / action 
taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts 
of interest.
(Not Applicable)
8.	
Number of days of accounts payables ((Accounts payable *365)/ Cost of goods/services procured) in the 
following format:
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Number of days of accounts payables
13 days
25 days
9.	
Open-ness of business  
	
Provide details of concentration of purchases and sales with trading houses, dealers, and related parties 
along-with loans and advances & investments, with related parties, in the following format: 
Parameter
Metrics
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Concentration of 
Purchases
a.
Purchases from trading houses as % of 
total purchases
18.69 %
22.82 %
b.
Number of trading houses where 
purchases are made from
23
19
c.
Purchases from top 10 trading houses as 
% of total purchases from trading houses
87.76 %
87.41 %
Concentration of 
Sales
a.
Sales to dealers/ distributors as % of 
total sales
77.47 %
81.35 %
b.
Number of dealers/ distributors to whom 
sales are made
2491
2625
c.
Sales to top 10 dealers/ distributors as % 
of total sales to dealers/ distributors
8.69 %
7.56 %
Share of RPTs in
a.
Purchases (Purchases with related 
parties/ Total Purchases)
7.69 %
13.81 %
b.
Sales (Sales to related parties/ Total 
Sales)
-
-
c.
Loans & Advances (Loans & advances 
given to related parties/ Total loans & 
advances)
-
-
d.
Investments (Investments in related 
parties/ Total Investments made)
-
-
Leadership Indicators
1.	
 Awareness programmes conducted for value chain partners on any of the principles during the financial 
year.
The Company collaborates with partners who resonate with its core values. In the case of any deviation or observed 
non-compliance in the operations of value chain partners, requisite corrective actions are taken.
2.	
Does the entity have Processes in place to avoid/manage conflict of interests involving members of the 
Board? (Yes/No) If yes, provide details of the same.
The Company’s code of conduct creates an awareness among Board of Directors in relation to conflict of interest 
and define procedures to avoid/manage any potential conflict of interest that may arise. In case of any such situation, 
company proactively take necessary steps to resolve the same before creation of any impact.
The Board of Directors also submits a declaration to the Company on an annual basis for compliance with Code 
of Conduct.
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
72
B.	
Principle 2: Businesses should provide goods and services in a manner that is sustainable and safe.
As an organisation that prioritises the well-being of our patients, we are dedicated to delivering high-quality products 
that are safe for our users. We have put in place thorough procedures to ensure the quality of our products at every 
stage until they reach the consumers. Our product packaging for all our brands includes comprehensive details to 
ensure the safety of our consumers. We take proactive measures to identify and address any potential risks or issues 
associated with our products. Our procedures comply with Good Manufacturing Practice (GMP) regulations and other 
quality standards outlined in the JPL Quality Management System. By adhering to GMP, we consistently produce and 
maintain the highest quality standards for medicinal products.
Essential Indicators
1.	
Percentage of capital expenditure (capex) investments in specific technologies to improve the 
environmental and social impacts of product and processes to total capex investments made by the entity.
The primary area of our operations lies in the marketing and distribution of pharmaceuticals. Hence, the above 
statement is relevant to us majorly in terms of information technology capital expenditure. No such capital 
expenditure has been incurred in FY 2024.
2.	
a. Does the entity have procedures in place for sustainable sourcing? (Yes/No)
Yes, the Company sources the finished formulation from leading contract manufactures who have implemented 
sustainable sourcing practices in-line with the global practices.
	
b. If yes, what percentage of inputs were sourced sustainably?
100% of inputs sourced sustainably by our contract manufacturers.
3.	
Describe the processes in place to safely reclaim your products for reusing, recycling, and disposing at the 
end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.
The Company has established procedures for the safe disposal of all the damaged and hazardous waste 
via incineration.
(a) 	 Plastics (including packaging) - The company operates in pharmaceuticals industry where re-use and 
recycling of pharmaceutical products is not involved. 
(b) 	 E-waste- The Company has established procedures for the safe disposal of waste via applicable practices. 
(c) 	 Hazardous waste - Since the Company is involved in marketing and distribution of pharmaceutical products, 
it has no exposure to generation of hazardous waste. 
(d) 	 Other waste - Apart from the things specified above, no other form of waste is produced by the Company. 
4.	
Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes / No). If 
yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan 
submitted to Pollution Control Boards? If not, provide steps taken to address the same Extended Producer 
Responsibility (EPR) is applicable to the entity’s activities.
Although the Extended Producer Responsibility (EPR) does not apply to our entity’s activities, we are dedicated 
towards environmentally sustainable waste management practices. In accordance with the guidelines set by the 
Central Pollution Control Board (CPCB), the company ensures the proper disposal of all types of waste. This includes 
expired and damaged goods, which are handed over to government-approved vendors for recycling or incineration, 
depending on the appropriate method. By adhering to these waste management processes, we prioritise responsible 
and eco-friendly practices in our operations.
Leadership Indicators
1.	
Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing 
industry) or for its services (for service industry)? If yes, provide details in the following format?
NIC Code
Name of 
Product/
Service
% of total 
Turnover 
contributed
Boundary for which the 
life cycle Perspective/ 
Assessment was 
conducted
Whether conducted by 
independent external 
agency (Yes/No)
Results communicated 
in public domain.
(yes/No) If yes, provide 
the web-link
Not Applicable on us, since the Company is not involved in Manufacturing 
2.	
If there are any significant social or environmental concerns and/or risks arising from production or 
disposal of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or 
through any other means, briefly describe the same along-with action taken to mitigate the same.
Name of Product/Service
Description of the risk/concern
Action Taken
Not Applicable on us, since the Company is not involved in Manufacturing
Business Responsibility and Sustainability Report  | Statutory Reports  ●
73
3.	
Percentage of recycled or reused input material to total material (by value) used in production (for manu-
facturing industry) or providing services (for service industry).
Indicate input material
Recycled or re-used input material to total material
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Not Applicable on us, since the Company is not involved in Manufacturing
4.	
Of the products and packaging reclaimed at end-of-life of products, amount (in metric tonnes) reused, 
recycled, and safely disposed of
The company has established a process for facilitating the return of expired and damaged products to ensure 
their efficient disposal through authorised waste management agencies, specifically through incineration. We also 
obtain certificates as part of our quality control measures to certify the efficient disposal, ensuring that there is no 
possibility of expired or damaged products re-entering the market. This rigorous process minimises potential risks 
to consumer health that may result from consuming expired or damaged products.
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Re-Used
Recycled
Safely Disposed
Re-used
Recycled
Safely Disposed
Plastics  
(Including packaging)
-
-
 Total expired goods 
and damaged goods 
sent for disposal - 
25978 Kg
-
-
Total expired goods 
and damaged 
goods sent for 
disposal - 4675 Kg
E-waste
-
-
-
-
Hazardous
-
-
-
-
Other waste
-
-
-
-
5.	
Reclaimed products and their packaging materials (as percentage of products sold) for each product 
category.
Indicate product category
Reclaimed products and their packaging materials as % of total products sold 
in respective category
Not Applicable
Not Applicable
C.	
Principle 3: Businesses should respect and promote the well-being of all employees, including those in their 
value chain.
The Company strives to align the individual goals of its employees with organisational goals. It considers its employees 
as human capital. Systems are in place to adequately reward and recognise deserving employees, which simultaneously 
acts as motivation for them to achieve better results.
Essential Indicators
1.	
(a) Details of measures for the well-being of employees
All employees are covered by well-being measures such as health and life insurances, accident insurance and 
maternity and other benefits (if applicable) as mentioned below:
Category
Health 
Insurance
Life/Accident
Insurance
Maternity 
Benefits
Paternity 
Benefits
Day Care 
Facilities
Total
(A)
No.
(B)
%
(B/A)
No.
(C)
%
(C/A)
No.
(D)
%
(D/A)
No.
(E)
%
(E/A)
No.
(F)
%
(F/A)
Permanent Employees
Male
1005
100%
1005
100%
-
-
1005
100%
0
0
1005
Female
20
100%
20
100%
20
100%
0
0%
0
0
20
Total
1025
1025
20
1005
0
0
1025
Other than Permanent Employees
Male
7
78%
9
100%
0
0%
9
100%
0
0
9
Female
0
0%
1
100%
1
100%
0
0%
0
0
1
Total
1032
1035
21
1014
0
0
1035
	
(b) Details of measures for the well-being of workers:
Category
Health 
Insurance
Life/Accident
Insurance
Maternity 
Benefits
Paternity 
Benefits
Day Care 
Facilities
Total
(A)
No.
(B)
%
(B/A)
No.
(C)
%
(C/A)
No.
(D)
%
(D/A)
No.
(E)
%
(E/A)
No.
(F)
%
(F/A)
Permanent Workers
0
0%
0
0%
0
0%
0
0%
0
0%
0
Other than 
Permanent Workers
5
100%
4
80%
0
0%
5
100%
5
100%
5
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
74
	
	
(c) Spending on measures towards well-being of employees and workers (including permanent and other 
than permanent) in the following format – 
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Cost incurred on well-being measures as a % of total 
revenue of the company
0.20
0.21
2.	
Details of retirement benefits, for Current Financial Year and Previous Financial Year
Benefits
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
No. of 
employees 
covered as 
a % of total 
employees
No. of 
workers 
covered as 
a % of total 
workers
Deducted and 
deposited 
with the 
authority 
(Y/N/N.A.)
No. of 
employees
covered as 
a % of total 
employees
No. of 
workers 
covered as 
a % of total 
workers
Deducted and 
deposited 
with the 
authority 
(Y/N/N.A.)
PF
100
-
Y
100
-
Y
ESI
17
-
Y
100
-
NA
Gratuity
100
-
N
46
-
 Y 
Others
-
-
-
-
-
-
3.	
Accessibility of workplaces
Are the premises/ offices of the entity accessible to differently abled employees and workers, as per the 
requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken 
by the entity in this regard.
Currently, the Company does not have any employee who is differently-abled. Our Corporate office is situated 
in Gurugram, Haryana which is easily locatable and is equipped with necessary features to accommodate 
differently-abled employees. Our dedication towards promotion of well-being of our employees inspires us to go 
beyond compliance.
4.	
Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? 
If so, provide a web-link to the policy.
The Company believes in equality of opportunity for all persons irrespective of any disability. We recruit people 
basis their skills, knowledge ad overall behaviour. We strives to build a healthy workplace wherein no discrimination 
can be tolerated on the basis of disability, gender, etc. We have not formulated a separate equal opportunity policy, 
however, our human resource policies do not contain any separate provision for disabled person making him feel 
inferior to others and we fosters to grow together with all or human assets.
Whistle blower policy is available at: https://www.jagsonpal.com/investor-relations.
5.	
Return to work and Retention rates of permanent employees and workers that took parental leave.
Permanent employees
Permanent workers
Gender
Return to work rate
Retention rate
Return to work rate
Retention rate
Male
100
100
-
-
Female
95
95
-
-
Total
100
100
-
-
6.	
Is there a mechanism available to receive and redress grievances for the employees and workers?
We strives to create a healthy and safe workplace for our employees wherein they can raise their concerns, provide 
suggestions on any matters. The Company consider their concerns or suggestions. Our whistle blower policy guides 
the employees for reporting their genuine concerns regarding any unethical behavior observed or suspected fraud 
or violation of company’s code of conduct. This policy contains provisions also with respect to protection of said 
person from victimisation.
We have constituted an Internal Complaints Committee under Prevention, Prohibition and Redressal of Sexual 
Harassment of Women at workplace Act, 2013 (“POSH Act”). The Company endeavours to create awareness among 
its employees regarding the Act and zero tolerance in violation of the same. The Company conducts training session 
annually on POSH which educates its employees on importance of compliance with POSH and issues which can 
arise on violation of POSH Act. The Company address any such concern seriously and conduct formal investigation 
whenever required.
Yes/No
(If yes, then give details of the mechanism in brief)
Permanent Workers
-
Other than Permanent Workers
-
Permanent Employees
Yes
Other than Permanent Employees
Yes
Business Responsibility and Sustainability Report  | Statutory Reports  ●
75
7.	
Membership of employees and workers in association(s) or Unions recognised by the listed entity:
The Company does not have any employee association(s) or Unions. Hence this parameter is not applicable.
Category
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Total 
employees/
workers in 
respective 
category
(A)
No. of 
employees/
workers in 
respective 
category, who 
are part of 
association(s) or 
Union.(B)
% 
(B/A)
Total 
employees/
workers in 
respective 
category
(C)
No. of 
employees/
workers in 
respective 
category, who 
are part of 
association(s) or 
Union. (D)
% 
(D/C)
Total
Permanent Employees
-
-
-
-
-
-
Male
-
-
-
-
-
-
Female
-
-
-
-
-
-
Total
Permanent Workers
-
-
-
-
-
-
Male
-
-
-
-
-
-
Female
-
-
-
-
-
-
8.	
Details of training given to employees and workers
The various trainings conducted by Learning and Development function, throughout the year 2023-24, include:
a.	
Managerial Skill Development programmes: 5 sessions; 40 participants
b.	
69 Induction & Refresher Training programmes have been conducted for 674 newly inducted employees to 
cover job specific requirements.
c.	
Additionally, 27 sessions have been conducted for refresher training of existing employees on Communication, 
Detailing and In-Clinic Performance skills, and Objection Handling.
d.	
31 Sessions on POSH have been conducted throughout the year covering 781 Participants
	
In the year 2022-23:
a.	
Role/ Function-based specific training and Skill Upgradation training: 17 sessions were conducted which were 
attended by 601 participants including both existing and newly inducted employees. The key areas in which 
such training was conducted included Communication, Detailing and In-Clinic Performance skills, Managerial 
skills, Objection Handling and MS-Excel skills.
b.	
56 Induction programmes have been conducted for 359 newly inducted employees to cover job 
specific requirements.
9.	
Details of performance and career development reviews of employees and worker:
The Company has formulated criteria for reward and recognition to deserving candidates. We have implemented 
adequate measures for employees individual growth and development by conducting sessions periodically. Our 
performance cycle for employees is from April to March. The increment in remuneration for an employee depends 
on company’s growth coupled with his/her individual performance during the year.
	
Principle 3: Essential Indicators
Answer to Question No. 9: Details of Performance and Career development reviews of employees and worker
Category
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Total (A)
No. (B)
% (B/A)
Total (C)
No. (D)
% (D/C)
Employees
Male
1014
591
58%
925
294
68%
Female
21
13
62%
15
3
53%
Total
1035
604
58%
 940
297
68%
Workers
Male
5
5
100%
NA
NA
NA
Female
0
0
-
NA
NA
NA
Total
5
5
100% 
NA
NA
NA
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
76
10.	 Health and safety management system:
a.	
Whether an occupational health and safety management system has been implemented by the entity? 
(Yes/ No). If yes, what is the coverage of such a system?
The company is involved in the sale and distribution of pharmaceutical products. Since the company is not 
involved in manufacturing, its employees do not have direct exposure to health and safety risks. However, 
the company is committed to protecting its employees from any issues that may arise in the normal course 
of business. The company complies with directives and guidelines issued by the government for the well-
being of its employees. The company understands the importance of the physical and mental well-being of 
its employees and prioritises it.
b.	
What are the processes used to identify work-related hazards and assess risks on a routine and non-
routine basis by the entity?
Company takes action on regular basis to identify any work-related hazards for its employees and initiate 
process accordingly to mitigate such risks.
c.	
Whether you have processes for employees to report the work-related hazards and to remove 
themselves from such risks.
The Company endeavours to create an understanding among its employees about the potential safety risks 
that may probably arise and are encouraged to highlight the same.
d.	
Do the employees/ workers of the entity have access to non-occupational medical and healthcare 
services?
The Company has undertaken a Group Mediclaim Policy, EDLI & Term Life Insurance and Group Accidental 
Insurance Policies for all of its employees, where Group Mediclaim Policy provides an option to employee to 
include their dependents in the same. Additionally, Company also conducts a full body health checkup of all 
the employees to ensure their overall well-being.
11.	 Details of safety-related incidents:
Safety Incident/Number
Category*
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Lost Time Injury Frequency Rate (LTIFR) (Per 
one million-person hours worked)
-
Nil
Nil
Total recordable work-related injuries
-
19 road accidents were 
recorded in FY2023-
24 where employees, 
covered under Group 
Mediclaim & Accident 
Insurance policies were 
provided with monetary 
support for their 
hospitalisation and post 
discharge health support.
3 road accidents were 
recorded in FY2022-
23 where employees, 
covered under Group 
Mediclaim policy were 
provided with monetary 
support for their 
hospitalisation and post 
discharge health support.
No. of fatalities
-
1
Nil
High consequence works related injury or 
ill-health (excluding fatalities)
-
Nil
Nil
*including the contract workforce
12.	 Describe the measures taken by the entity to ensure a safe and healthy workplace.
The Company endeavours to maintain a safe and healthy workplace for its employees both in terms of mental and 
physical health by implementing necessary measures in this regard. Additionally, we endeavour to remain compliant 
with guidance issued by concerned regulatory authorities in this regard.
a.	
Proper systems have been devised to ensure compliance with safety standards along with maintenance of 
proper hygiene in office premises.
b.	
Company has conducted a full body health check-up drive for all employees at its own cost to maintain a 
healthy workforce.
13.	 Number of complaints on the following made by employees and workers.
Benefits
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Filed during 
the year
Pending 
resolution at 
the end of year
Remarks
Filed during 
the year
Pending 
resolution at 
the end of year
Remarks
Working Conditions
0
0
0
0
0
0
Health & Safety
0
0
0
0
0
0
Business Responsibility and Sustainability Report  | Statutory Reports  ●
77
14.	 Assessments for the year
Health and safety practices Regular checks have been conducted to ensure the proper functioning of health and 
safety measures for employees.
Working Conditions
The Company aims to ensure excellent working conditions at its office premises and 
to comply with all relevant laws and regulations regarding fair working conditions 
and labour laws.
15.	 Provide details of any corrective action taken or underway to address safety-related incidents (if any) 
and on significant risks / concerns arising from assessments of health and safety practices and working 
conditions.
The company is engaged in selling and distribution of products, hence this is not directly applicable basis nature 
of the business. However, the Company undertake necessary measures regularly, which have been covered in 
aforesaid points.
Leadership Indicators
1.	
 Does the entity extend any life insurance or any compensatory package in the event of death?
The company has implemented various employee benefit policies, including the EDLI Policy and Group Term Life 
Insurance Policy. These policies are prioritised in the event of an employee’s death.
2.	
Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and 
deposited by the value chain partners.
Value chain partners are third parties, that’s why the Company does not deduct any statutory dues.
3.	
Provide the number of employees / workers having suffered high consequence work- related injury / 
ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been rehabilitated and 
placed in suitable employment or whose family members have been placed in suitable employment.
Total no. of affected employees/
workers
No. of employees/workers that are 
rehabilitated and placed in suitable 
employment or whose family 
members have been placed in suitable 
employment
FY 2023-24
(Current 
Financial Year)
FY 2022-23
(Previous 
Financial Year)
FY 2023-24
(Current Financial 
Year)
FY 2022-23
(Previous 
Financial Year)
Employees
0
0
0
0
Workers
0
0
0
0
4.	
Does the entity provide transition assistance programmes to facilitate continued employability and the 
management of career endings resulting from retirement or termination of employment? (Yes/ No)
We firmly believe in personal growth of our employees. Effective measures are taken by learning and development 
function to build new competencies, knowledge, and skills to help our employees upgrade their skills, grow and 
stay ahead of the curve which facilitates continuation of employment post-retirement or termination.
5.	
Details on assessment of value chain partners
We have efficient mechanisms in place to identify value chain partners. Proper measures are taken to identify risks 
associated in collaboration with such value chain partners and appropriate actions are taken to mitigate risks arising 
from such collaboration. We have a defined set of parameters for identification of risks.
6.	
 Provide details of any corrective actions taken or underway to address significant risks/concerns arising 
from assessments of health and safety practices and working conditions of value chain partners.
Proper checking systems have been implemented to identify concerned risks arising from collaboration with value 
chain partners. The concentration level of risks pertaining to value chain partners are assessed on the basis of 
their established systems and processes. Appropriate mitigation strategies adopted to tackle such risks including 
health and safety.
In FY 2022-23: No physical audits or assessments were carried out due to the COVID pandemic.
In FY 2023-24: No case was found where corrective action was required.
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
78
D.	
Principle 4: Businesses should respect the interests of and be responsive to all its stakeholders.
	
The Company believes in upholding the interests of all stakeholders and aims to maximise their value. It recognises the 
importance of stakeholders in fostering success. The Company remains committed to earn the trust and support of its 
stakeholders by providing quality services.
Essential Indicators
1.	
Describe the processes for identifying key stakeholder groups of the entity.
The Company considers stakeholders as a cornerstone of the success of our business. We set certain guidelines and 
set of principles for our stakeholders. Being operated in the pharmaceutical industry, our patients are one of our 
key stakeholders. We strives to meet expectation of our stakeholders which enables us to earn our stakeholder’s 
confidence in us. We engage with our stakeholders on a periodic basis to obtain their feedback.
2.	
List stakeholder groups identified as key for the entity and the frequency of engagement with each stake-
holder group.
Stakeholder 
Group
Channels of communication 
(Email, SMS, Newspaper, 
Pamphlets, Advertisement, 
Community Meetings, Notice 
Board, Website), Other
Frequency of
engagement
Purpose and scope of engagement including key 
topics and concerns raised during such engagement
Patients and 
consumers
Webinars, Social media 
pages, Posters, Standees, 
Pamphlets
Ongoing and 
need based
Disease awareness programmes are organised 
to educate the general public about the signs, 
symptoms and diagnosis, treatment and prevention 
options for a disease to foster better patient 
outcomes through prevention, early diagnosis 
and management to minimise or slow disease 
progression and complications.
Healthcare 
Professionals 
(HCPs)
Face to face meetings, 
Emails, Webinars, Social 
media pages, Posters, 
Standees, Pamphlets, Doctor 
networking platforms, SMSs, 
Instant platforms etc.
Ongoing and 
need based
Keep the HCP abreast with the latest information 
on disease, science of our product and disease 
management through our product.
To provide avenues for HCPs to discuss and 
deliberate on latest data, clinical challenges and 
multidisciplinary expert discussions intending to help 
in improving treatment outcomes for the patients.
We ensure responsible sales and marketing practices, 
in compliance with local laws and applicable industry 
codes, while interacting with HCPs.
Investors and 
Shareholders
Annual General Meetings, 
Emails, Newspaper/ Press 
Release, Advertisement, 
Notices, Website, Intimation 
to Stock Exchanges, Annual/ 
Quarterly Financials and 
Investor Presentation, 
Annual Reports
At least 
quarterly and 
need based
To stay abreast of developments in the Company, 
Performance of the Company and address concerns/
grievances
Communities 
and NGOS
Emails, Physical meetings, 
Website and other digital 
platforms.
Need based
Implementing and monitoring the CSR activities
Government 
and Drug 
Regulators
Emails, Submissions 
through online Regulatory 
Agency portals or direct 
submissions to Regulatory 
Agency office
Need based
Policy 
and 
Regulatory 
Matters, 
Grant 
and 
maintenance of licenses pertaining to manufacturing 
and marketing of our products, pricing of medicines 
and other regulatory approvals
Suppliers and 
Distributors
Emails, physical meetings, 
website and other digital 
platforms
Ongoing and 
need based
Quality of material, commercial and technical terms 
of payment and delivery, compliance to our ethics, 
ways of working and statutory requirements
Employees
Direct, email, town halls and 
team meetings.
Ongoing and 
need based
Performance 
Appraisal, 
Training 
and 
Career 
Development, 
Wellness 
and 
safety 
measures, 
Rewards and Recognitions
Business Responsibility and Sustainability Report  | Statutory Reports  ●
79
Leadership Indicators
1.	
Provide the processes for consultation between stakeholders and the Board on economic, environmental, 
and social topics or if consultation is delegated, how is feedback from such consultations provided to the 
Board.
Refer answer to Question 2 of essential indicators.
2.	
Whether stakeholder consultation is used to support the identification and management of environmental, 
and social topics (Yes / No). If so, provide details of instances as to how the input received from stakeholders 
on these topics were incorporated into policies and activities of the entity.
Refer answer to Question 2 of essential indicators
3.	
Details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ 
marginalised stakeholder groups.
Being a part of society and a good corporate citizen, the company recognises its duty to create a positive impact on 
society specially on weaker sections of the society. The Company’s CSR initiatives primarily focus on two core areas:
•	
Education and Livelihood
•	
Health and Sanitation
Company has constituted a CSR Committee in terms of applicable provisions of the Companies Act, 2013 which 
review the progress in CSR initiatives on regular basis. Through its ongoing projects, company is focusing on the 
following areas:
•	
Promotion of Menstruation Hygiene
•	
Environmental Cleanliness
In pursuance of its CSR initiatives, Company has launched a website named “My Sakhi” focusing specifically on 
the topic of Menopause. The Company has built toilets, in collaboration with Sulabh International Social Service 
Organisation, with emphasis around women schools and public places.
E.	
Principle 5: Businesses should respect and promote human rights.
The Company recognises the importance of fundamental human rights and is dedicated to protecting them. It prohibits 
any act or omission that violates an individual's human rights. The Company continuously strives to create a wholesome 
and secure work atmosphere for its employees, free from any kind of discrimination. To protect the dignity and human 
rights of its employees, the Company has formulated various policies, including the Prevention of Sexual Harassment 
Policy, Whistleblower Policy, and Code of Conduct.
Essential Indicators
1.	
Employees and workers who have been provided training on human rights issues and policies of the entity.
Our employees have been given training for professional development that focus on enhancing employees' 
professional skills, behaviour, and conduct in the workplace. Apart from professional development, employees 
are trained on prevention of sexual harassment as well to sensitise them towards gender diversity. 781 employees 
attended POSH training in 2023-24
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Total
(A)
No. of 
employees 
/ workers 
covered.
(B)
% (B/A)
Total
(C)
No. of 
employees/ 
workers 
covered.
(D)
% (D/C)
Employees
Permanent Employees
1025
776
76%
940
829
88%
Other than Permanent Employees
10
5
50%
-
-
-
Total
1035
781
75%
940
829
88%
Workers
Permanent Workers
-
-
-
-
-
-
Other than Permanent Workers
5
-
-
-
-
-
Total
5
-
-
-
-
-
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
80
2.	
Details of minimum wages paid to employees and workers, in the following format
Category
FY 2023-24
 Current Financial Year
FY 2022-23 
Previous Financial Year
Total
(A)
Equal to 
minimum wage
More than 
minimum wage
Total
(D)
Equal to 
minimum wage
More than 
minimum wage
B
% (B/A)
C
%(C/A)
E
% 
(E/D)
F
% (F/D)
Employees
Permanent
Male
1005
-
-
1005
100%
925
-
-
925
100%
Female
20
-
-
20
100%
15
-
-
15
100%
Other than Permanent
Male
9
-
-
9
100%
-
-
-
-
-
Female
1
-
-
1
100%
-
-
-
-
-
Workers
Permanent
Male
-
-
-
-
-
-
-
-
-
-
Female
-
-
-
-
-
-
-
-
-
-
Other than Permanent
Male
5
-
-
5
100%
-
-
-
-
-
Female
-
-
-
-
-
-
-
-
-
3.	
Details of remuneration/salary/wages
	
	
a. Median remuneration/ wages:
(In Millions)
Male
Female
Number
Median remuneration/ 
salary/ wages of 
respective category
Number
Median remuneration/ 
salary/ wages of 
respective category
Board of Directors (including MD)
4
1,00,00,000
2
0
Key Managerial Personnel (CFO and CS)
2
32,00,306
0
0
Employees other than BOD and KMP
1,016
3,35,232
21
3,50,004
Workers 
5
2,45,820
0
0
Other
0
0
0
0
b.	
Gross wages paid to females as % of total wages paid by the entity, in the following format:
FY 2023-24
FY 2022-23
Gross wages paid to females as % of total wages
2.2%
2.3%
4.	
Do you have a focal point (Individual/ Committee) responsible for addressing human  rights impacts or 
issues caused or contributed to by the business? (Yes/No)
At Jagsonpal, Mr. Bharat Chugh, General Manager, Human Resource is responsible to ensure effective resolution 
of any matter related to human rights caused by the business.
5.	
Describe the internal mechanisms in place to redress grievances related to human rights issues
Any matter which is unethical or is in violation of human rights of any individual can be reported to the General 
Manger, Human Resources, who proactively addresses the matter and undertakes suitable action to resolve the 
same. We have constituted an internal committee under policies like Prevention of Sexual Harassment of Women 
at workplace, Whistle blower, Grievance Redressal, etc which is solely responsible to address and resolve matters 
of violation.
6.	
Number of Complaints on the following made by employees and workers
We have not received any complaint regarding child labour, forced labour, wages, sexual harassment and 
discrimination at workplace in the current or previous financial year.
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Filled 
during 
the year
Pending 
resolution at the 
end of the year
Remarks
Filed 
during 
the year
Pending 
resolution 
during the year
Remarks
Sexual Harassment
0
0
NA
0
0
NA
Discrimination at workplace
0
0
NA
0
0
NA
Child Labour
0
0
NA
0
0
NA
Forced Labour/ Involuntary Labour
0
0
NA
0
0
NA
Wages
0
0
NA
0
0
NA
Other human rights related issues
0
0
NA
0
0
NA
Business Responsibility and Sustainability Report  | Statutory Reports  ●
81
7.	
Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and 
Redressal) Act, 2013, in the following format: 
FY 2023-24
FY 2022-23
Total Complaints reported under Sexual Harassment of Women at 
Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)
0
0
Complaints on POSH as a % of female employees / workers
0
0
Complaints on POSH upheld
0
0
8.	
Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.
The company has established effective mechanisms to prevent victimisation of individuals in cases of discrimination 
and harassment. We have an internal committee to address cases under the Prevention, Prohibition, and Redressal 
of Sexual Harassment of Women at Workplace Act of 2013. This committee is authorised to take disciplinary action, 
including dismissal, against any person who threatens or takes revenge against a complainant. Our company has 
a zero-tolerance policy for such behavior.
9.	
Do human rights requirements form part of your business agreements and contracts? (Yes/No)
The Company aims to operate ethically in a transparent manner. We emphasis the importance of human rights 
in our core values. We enter into deal with only such parties who meets with our criteria regarding compliance of 
human right matters. Preliminary evaluation activity has been conducted before entering into any agreement and 
contract to check the core values of counter party. We prevent engagement in unethical practices violating human 
rights such as child labour, forced labour, minimum wages, working hours, etc.
10.	 Assessments of the year
Our mechanisms for such kind of matters has been internally reviewed by the Company to reduce the risk of non-
compliances and no such non-compliances has been observed.
% of your plants and offices that were assessed
(By entity or statutory authorities or third parties)
Child Labour
0
Forced/Involuntary Labour
0
Sexual Harassment
0
Discrimination at Workplace
0
Wages
0
Other-please specify
0
11.	 Provide details of any corrective actions taken or underway to address significant risks / concerns arising 
from the assessments at Question 10 above.
Not Applicable since there were no cases recorded for the significant risks/concerns mentioned at Question 10 
during the year under review.
Leadership Indicators
1.	
Details of a business process being modified/introduced because of addressing human rights grievances/
complaints.
During the year under review there were no instances of human rights violation recorded and no complaints lodged. 
Accordingly, requirement of modification/introduction of a business process didn’t arise.
2.	
Details of the scope and coverage of any Human rights due diligence conducted.
The Company respects human rights and is dedicated to the protection of the same. It discourages any kind 
of activity that violates human rights in any way, for example, child labour, forced labour, human trafficking, 
discrimination, etc. The Company has zero tolerance against any act that is violative of human rights.
3.	
Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the 
Rights of Persons with Disabilities Act, 2016?
Our corporate office is situated in Gurugram, Haryana, is easily locatable and accessible to differently abled visitors 
and is equipped with necessary infrastructural requirements for differently abled visitors.
4.	
Details on assessment of value chain partners:
As part of the Company’s on-boarding process, all third-party vendors, suppliers, and contract manufacturers, are 
evaluated regarding compliance on human rights matters like child labour, forced labour, non-discriminatory, safe 
and healthy workplace, minimum wages, working hours etc. Upon satisfactory assessment of their policies and 
procedures on said matters, they are engaged subject to their assurance and commitment towards Jagsonpal’ s 
value system.
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
82
% of Value chain partner
(By value of business done with such partners) that were assessed
Child Labour
0
Forced/Involuntary Labour
0
Sexual Harassment
0
Discrimination at Workplace
0
Wages
0
Other-please specify
0
5.	
Provide details of any corrective actions taken or underway to address significant risks / concerns arising 
from the assessments at Question 4 above.
There was no requirement to implement any corrective measures as no significant risks. Concerns has been arisen 
from assessment of value chain partners as mentioned in answer to Question 4 above.
F.	
 Principle 6: Businesses should respect and make efforts to protect and restore the environment.
	
The Company acknowledges its responsibility to safeguard the environment. It is enhancing its systems and procedures 
by adopting a technology-driven approach and reducing its reliance on practices that negatively impact the environment. 
The Company is committed to minimising its environmental footprint and contributing to environmental restoration. 
Additionally, it has implemented efficient waste management initiatives and established a system for disposing of 
damaged and expired goods through incineration.
Essential Indicators
1.	
Details of total energy consumption (in Joules or multiples) and energy intensity:
(Note: below data is for Corporate Office and warehouse)
9,41,134 Units (kwh/kvah) has been total electricity consumption at Corporate Office and warehouse.
2.	
Does the entity have any sites/facilities identified as designated consumers (DCs) under the Performance, 
Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set 
under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial 
action taken, if any.
The company does not have any sites or facilities identified as designated consumers (DCs) under the Perform, 
Achieve, and Trade (PAT) Scheme of the Government of India.
3.	
Provide details of the following disclosures related to water:
The Company recognises the significance of water for human survival and is committed to minimising its wastage in 
every possible way. Since the Company is engaged only in the selling and distribution of pharmaceutical products, 
its water usage is limited to human consumption at the corporate office. The Company is dedicated to using water 
prudently and remains focused on its sustainable use.
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? 
(Y/N) If yes, name of the external agency.
The Company internally evaluates its usage of water.
4.	
Provide the following related to water discharged:
Not Applicable, since company use water for drinking purpose at its corporate office.
FY 2023-24
FY 2022-23
Water discharge by destination and level of treatment (in kiloliters) 
i.	
To Surface water
NA
NA
-	
No treatment
-	
With treatment – please specify level of treatment
ii.	
To Groundwater
NA
NA
-	
No treatment
-	
With treatment – please specify level of treatment
iii.	
To Seawater
NA
NA
-	
No treatment
-	
With treatment – please specify level of treatment
iv.	
Sent to third parties
NA
NA
-	
No treatment
-	
With treatment – please specify level of treatment
v.	
Others
NA
NA
-	
No treatment
-	
With treatment – please specify level of treatment
Total water discharged (in kilolitres)
NA
NA
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of 
the external agency.
Business Responsibility and Sustainability Report  | Statutory Reports  ●
83
5.	
Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage 
and implementation.
The company’s usage of water is limited to human consumption as it does not have a manufacturing plant. The 
company encourage its employees to use water in a sustainable manner reducing its wastage.
6.	
Please provide details of air emissions (other than GHG emissions) by the entity:
This parameter is not applicable since the company is not operating any manufacturing plant.
7.	
Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) and its intensity:
Not applicable since the company is not operating any manufacturing plant.
8.	
Does the entity have any project related to reducing Greenhouse Gas emissions? If Yes, then provide 
details.
Not applicable since the company is not operating any manufacturing plant.
9.	
Provide details related to waste management by the entity:
The company has established a system for effective waste disposal through waste management agencies. Because 
the company sells and distributes pharmaceutical products, there is a significant risk of product expiration. 
Therefore, products that are near expiry, expired, or damaged are considered as waste. Once identified, they 
are handed over to a Government CPCB authorised waste management agencies for efficient disposal by way of 
incineration. Certificates are obtained to ensure proper waste disposal, preventing the return of such products to 
the market and preserving consumer and environmental health.
Quantum of expired goods and damaged goods sent for disposal:
FY 2022-23: 4675 Kg (4.675 MT)
FY 2023-24: 25978 Kg (25.978 MT)
Parameters
FY 2023-24
(Current Financial 
Year)
FY 2022-23
(Previous Financial 
Year)
Total waste generated (in metric tonnes)
Plastic waste (A)
NA
0
E-waste (B)
NA
NA
Bio-medical waste (C)
NA
NA
Construction and demolition waste (D)
NA
0
Battery waste (E)
NA
0
Radioactive waste (F)
NA
NA
Other Hazardous waste. Please specify, if any. (G)
25.978
4.675
Other Non-hazardous waste generated (H). Please Specify, if any.
(Break-up by composition i.e., by materials relevant to the sector)
NA
0
Total (A+B+C+D+E+F+G+H)
25.978
4.675
Waste intensity per rupee of turnover
(Total waste generated/ Revenue from Operations)
NA
NA
Waste intensity per rupee of turnover adjusted for Purchasing 
Power Parity (PPP)
(Total waste generated/ Revenue from operations adjusted for PPP)
NA
NA
Waste intensity in terms of physical output
NA
NA
Waste intensity (optional)- the relevant metric may be selected by 
the entity
NA
NA
For each category of waste generated, total waste recovered through recycling, re-using or other 
recovery operations (in metric tonnes)
Category of waste
(i)	
Recycled
0
0
(ii)	
Re-used
0
0
(iii)	 Other recovery operations
0
0
Total
0
0
For each category of waste generated, total waste disposed by nature of disposal method. (in metric 
tons)
Category of Waste
(i)	
Incineration
25.978
4.675
(ii)	
Landfilling
0
0
(iii)	 Other disposal operations
0
0
Total
25.978
4.675
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of 
the external agency.
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
84
10.	 Briefly describe the waste management practices adopted in your establishments. Describe the strategy 
adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes 
and the practices adopted to manage such wastes.
This point is directly not applicable to the Company as it does not operate a manufacturing plant. The company 
outsources its product manufacturing through contract manufacturing arrangements. We get third plant 
manufacturing audited at regular intervals by our quality assurance department, to ensure its compliance 
with Central Pollution Control Board/State Pollution Control Board guidelines, and Hazardous and other waste 
(Management and Transboundary) Rules 2016.
11.	 If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife 
sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) 
where environmental approvals/clearances are required:
This parameter is not applicable on the Company as it does not have any offices in ecologically sensitive areas.
12.	 Details of environmental impact assessments of projects undertaken by the entity based on applicable 
laws, in the current financial year:
Basis notification of the Ministry of Environment, Forests and Climate Change (MOEFCC) in India, an Environmental 
Impact Assessment (EIA) required to be carried out for those industries which impact environment negatively. The 
Company is not required to perform an EIA pre-clearance by the MOEFCC as it is into marketing and distribution 
of pharmaceuticals and does not have any operations which could have any adverse impact on the environment.
Name and brief 
details of project
EIA Notification 
No.
Date
Whether conducted 
by Independent 
external agency (Yes/
No)
Results 
communicated in 
public domain.
(Yes/No)
Relevant Web 
Link
Not Applicable
13.	 Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such 
as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, 
Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, 
in the following format:
The Company remains compliant with the requisite environmental law/regulations/guidelines in India and there 
are no non-compliances reported for FY 2023-24.
S. 
No.
Specify the law/ regulation/ 
guidelines which was not 
complied with
Provide details of the 
non-compliance
Any fines / penalties/ action 
taken by regulatory agencies 
such as pollution control boards 
or by courts
Corrective action 
taken if any
Nil
Leadership Indicators
1.	
Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):
For each facility / plant located in areas of water stress, provide the following information:
i.	
Name of the area
ii.	
Nature of operations
iii.	
Water withdrawal, consumption, and discharge in the following format:
Parameters
FY 2023-24
(Current Financial 
Year)
FY 2022-23
(Previous Financial 
Year)
Water withdrawal by source (in kiloliters)
(i)
Surface water
Not Applicable
Not Applicable
(ii)
Groundwater
(iii)
Third-party water
(iv)
Seawater/ desalinated water
(v)
Others
Total volume of water withdrawal (in kilolitres)
Total volume of water consumption (in kilolitres)
Water intensity per rupee of turnover (Water consumed/
turnover)
Water intensity (optional) – the relevant metric may be selected 
by the entity
Business Responsibility and Sustainability Report  | Statutory Reports  ●
85
Parameters
FY 2023-24
(Current Financial 
Year)
FY 2022-23
(Previous Financial 
Year)
Water discharge by destination and level of treatment (in kiloliters)
(i)
Into surface water
NA
NA
-
No treatment
-
With treatment – please specify level of treatment
(ii)
Into Groundwater
NA
NA
-
No treatment
-
With treatment – please specify level of treatment
(iii)
Into Seawater
NA
NA
-
No treatment
-
With treatment – please specify level of treatment
(iv)
Sent to third-parties
NA
NA
-
No treatment
-
With treatment – please specify level of treatment
(v)
Others
NA
NA
-
No treatment
-
With treatment – please specify level of treatment
Total water discharged (in kilolitres)
NA
NA
Note: Indicate if any independent assessment/ evaluation/ assurance has been carried out by an external agency? (Y/N) If yes, name of 
the external agency.
Not Applicable since the company is not engaged in manufacturing.
2.	
Please provide details of total Scope 3 emissions & its intensity, in the following format:
Parameter
Unit
FY 2023-24
(Current Financial 
Year)
FY 2022-23
(Previous Financial 
Year)
Total Scope 3 emissions (Break-up of the GHG into 
CO2, CH4, N2O, HFCs, PFCs,
SF6, NF3, if available)
Metric tonnes of 
CO2
equivalent
NA
NA
Total Scope 3 emissions
per rupee of turnover
NA
NA
Total Scope 3 emission intensity (optional) – the 
relevant metric may be selected by the entity
NA
NA
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of 
the external agency.
Not Applicable since the company is not engaged in manufacturing.
3.	
With respect to the ecologically sensitive areas reported at Question 11 of Essential Indicators above, 
provide details of significant direct and indirect impact of the entity on biodiversity in such areas along-
with prevention and remediation activities.
Not applicable as the Company does not have operations in ecologically sensitive areas.
4.	
If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve 
resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please 
provide details of the same as well as outcome of such initiatives:
The Company’s carbon footprint is restricted to the use of consumables such as paper, plastic, water and energy as 
Company operates in marketing and distribution of pharmaceuticals and does not have its own manufacturing units.
S. 
No.
Initiative undertaken
Details of the initiative (Web-link, if any, may 
be provided along-with summary)
Outcome of the initiative
Not Applicable
5.	
Does the entity have a business continuity and disaster management plan?
The Company has formulated a business continuity plan to be implemented in case of any exigencies.
6.	
Disclose any significant adverse impact to the environment, arising from the value chain of the entity. 
What mitigation or adaptation measures have been taken by the entity in this regard?
The company does not operate a Manufacturing unit, it has no adverse impact on the environment. However, 
Company endeavours to minimise its impact on environment caused due to using plastic, paper, etc.
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
86
7.	
Percentage of value chain partners (by value of business done with such partners) that were assessed for 
environmental impacts.
The contract manufacturers and suppliers are assessed at the time of onboarding and periodically thereafter 
for compliance with Good Manufacturing Practices (GMP). It is also ensured that their standard operating 
procedures are aligned with the Company’s Quality Management System (QMS) through regular audits of contract 
manufacturing sites. Consequently, GMP, along with the Company’s QMS, ensures the mitigation of environmental 
risks in this regard.
G.	
Principle 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a manner 
that is responsible and transparent.
Essential Indicators
	
1.	
a. Number of affiliations with trade and industry chambers/ associations.
	
	
The Company is not a member of any trade and industry associations.
	
	
b. List the top 10 trade and industry chambers/ associations (determined based on the total members of 
such a body) the entity is a member of/ affiliated to.
S. 
No.
Name of the trade and industry chambers/ 
associations
Reach of trade and industry chambers/ associations
(State/National)
1.
NA
NA
This list of top 10 trades and industry associations is not applicable on the Company as Company is not a member 
of any trade and industry associations.
2.	
Provide details of corrective action taken or underway on any issues related to anti-competitive conduct 
by the entity, based on adverse orders from regulatory authorities.
There were no material instances reported or any orders received from regulatory authorities on any issues related 
to anti-competitive conduct by the entity.
Leadership Indicators
1.	
Details of public policy positions advocated by the entity:
S. 
No.
Public policy 
advocated
Method resorted for 
such advocacy
Whether information 
available in public 
domain (Yes/No)
Frequency of review by Board
(Annually/Half yearly/ 
quarterly/ Others – please 
specify)
Web Link, if 
available
Nil
H.	
Principle 8: Businesses should promote inclusive growth and equitable development
	
The Company firmly believes in promoting inclusive growth and equitable development. It aims to provide quality 
services at a reasonable cost, without any discrimination based on gender, caste, religion, background, etc. The Company 
has identified Health and Sanitation, as well as Education and Livelihood, as core areas for its CSR initiatives, which are 
designed to uplift marginalised communities.
Essential Indicators
1.	
Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, 
in the current financial year.
During the year under review, the Company has not undertaken Social Impact Assessment of any projects.
Name and 
brief details of 
project
SIA Notification 
No.
Date of 
notification
Whether conducted by 
independent external 
agency (Yes/No)
Results communicated 
in Public domain
(Yes/No)
Relevant Web 
link
NA
Business Responsibility and Sustainability Report  | Statutory Reports  ●
87
2.	
Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R & R) is being 
undertaken by your entity.
We operate in selling and distribution of pharmaceutical products, hence our operations does not resulted into 
community displacement. Therefore, requirement for Rehabilitation and Resettlement (R&R) does not arise.
Sr. 
No.
Name of the 
project for which 
R&R is ongoing
State
District
No. of projects affected 
Families (PAFs)
% of PAFs covered 
by R&R
Amounts paid to PAFs 
in the FY (In INR)
NA
3.	
Describe the mechanisms to receive and redress the grievances of the community.
Not Applicable
4.	
Percentage of input material (inputs to total inputs by value) sourced from supplier. 
Not Applicable
Parameter
FY 2023-24
(Current Financial 
Year)
FY 2022-23
(Previous Financial 
Year)
Directly sourced from MSMEs/ small producers
0
0
Directly from within India 
0
0
5.	
Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers 
employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total 
wage cost.
Parameter
FY 2023-24
(Current Financial 
Year)
FY 2022-23
(Previous Financial 
Year)
Rural 
 0.53%
0.69%
Semi-urban
1.99%
1.38%
Urban 
40.09%
40.87%
Metropolitan 
57%
57% 
(Place to be categorised as per RBI Classification System – rural/ semi-urban/ urban/ metropolitan)
Leadership Indicators
1.	
Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact 
Assessments
(Reference: Question 1 of Essential Indicators above):
Details of negative social impact identified
Corrective action taken
NA
NA
2.	
Provide the following information on CSR projects undertaken by your entity in designated aspirational 
districts as identified by government bodies:
Not Applicable
	
3.	
(a) Do you have a preferential procurement policy where you give preference to purchase from suppliers 
comprising marginalised /vulnerable groups? (Yes/No) - No
	
	
(b) From which marginalised /vulnerable groups do you procure? - Not Applicable
	
	
(c)What percentage of total procurement (by value) does it constitute? - Not Applicable
4.	
Details of the benefits derived and shared from the intellectual properties owned or acquired by your 
entity (in the current financial year), based on traditional knowledge:
S. 
No.
Intellectual Property based on 
traditional knowledge
Owned/Acquired
(Yes/No)
Benefit Shared
(Yes/No)
Basis of calculating 
benefit share
Nil
5.	
Details of corrective actions taken or underway, based on any adverse order in intellectual property related 
disputes wherein usage of traditional knowledge is involved.
Name of Authority
Brief of the case
Corrective action taken
Nil
6.	
Details of beneficiaries of CSR Projects:
To improve women’s hygiene and sanitation facilities, we have constructed four girls’ toilets at various locations in 
Uttarakhand and Punjab as part of our CSR initiatives. This aligns with our commitment to health and sanitation, 
benefiting approximately 2500 people.
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
88
I.	
Principle 9: Businesses should engage with and provide value to their consumers in a responsible manner
	
The Company strives to provide quality services with a prime focus on women’s health. It has implemented necessary 
procedures to ensure the delivery of safe and healthy products to consumers by ensuring compliance with Good 
Manufacturing Practices (GMP) by partnered contract manufacturers.
Essential Indicators
1.	
Describe the mechanisms in place to receive and respond to consumer complaints and feedback.
The Company has implemented efficient measures to address consumer complaints and feedback. It endeavours to 
resolve consumer complaints proactively and consider their valuable feedback to improve systems. Consumers can 
submit their complaints and feedback via email at info@jagsonpal.com; customercare@jagsonpal.com; Lycored@
jagsonpal.com as mentioned on the pack of products or call us at 0124-4406710 or send us the written complaint 
at our Corporate Office situated at Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Sector – 18, 
Gurugram -122015, Haryana (India)
2.	
Turnover of products / services as a percentage of turnover from all products/services that carry 
information about:
Particulars
As a percentage to the total turnover
Environmental and social 
parameters relevant to the product
Not applicable
Safe and responsible usage
100%
Recycling and/or safe disposal
Not applicable - While the Company does not specifically mention any 
such details on its products, it complies with all statutory requirements of 
the Pollution Control Boards etc.
3.	
Consumer complaints in respect of Data Privacy, Advertising, Cyber-Security, Delivery of Essential Services, 
Restrictive and Unfair Trade Practices.
No consumer complaints were received during FY 2023-24.
FY 2023-24
Current Financial Year
FY 2022-23
Previous Financial Year
Received 
during 
the year
Pending 
resolution at 
end of year
Remarks
Received 
during 
the year
Pending 
resolution at 
end of year
Remarks
Data Privacy
0
0
NA
0
0
NA
Advertising
0
0
NA
0
0
NA
Cyber- security
0
0
NA
0
0
NA
Delivery of essential services
0
0
NA
0
0
NA
Restrictive trade practices
0
0
NA
0
0
NA
Unfair trade practices
0
0
NA
0
0
NA
Other
0
0
NA
0
0
NA
4.	
Details of instances of product recalls on account of safety issues:
No product recalls have been made during FY 23-24.
Number
Reason for recall
Voluntary recalls 
0
0
Forced recalls 
0
0
5.	
Does the entity have a framework/policy on cyber security and risks related to data privacy? (Yes/No) If 
available, provide a web-link of the policy.
The Company has a world-class firewall and antivirus installed on its network. The Company has complete data 
protection and cloud backup solutions which are continuously being monitored by professionals to avoid data 
breaches and hacking threats. There exists 3-2-1 Data Protection and Recovery Plan; three copies of server data, 
two different types of media, and one air-gapped copy located offsite. The IT department is the custodian of policy 
on cyber security and risks related to data privacy.
	
6.	
Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery 
of essential services; cyber security and data privacy of customers; re-occurrence of instances of product 
recalls; penalty / action taken by regulatory authorities on safety of products / services.
During the year under review, all the complaints received from consumers were related to packaging of the products 
and there were no instances recorded for any issue in relation to cyber security and data privacy of customers; re-
occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products 
/ services.
Business Responsibility and Sustainability Report  | Statutory Reports  ●
89
7.	
Provide the following information relating to data breaches:
	
	
a.	
Number of instances of data breaches – Nil
	
	
b.	
Percentage of data breaches involving personally identifiable information of customers - NA
	
	
c.	
Impact, if any, of the data breaches - NA
Leadership Indicators
1.	
Channels / platforms where information on products and services of the entity can be accessed (provide 
web link, if available).
The information regarding the company’s products and services can be accessed at https://www.jagsonpal.com/.
2.	
Steps taken to inform and educate consumers about safe and responsible usage of products and/or 
services.
Steps Taken to Inform and Educate Consumers about Safe and Responsible Usage of Products and Services
a. Equipping Sales Representatives: Sales representatives are provided with visual aids to effectively disseminate 
information to Healthcare Professionals (HCPs).
b. Educational Sessions: The Company conducts sessions on the responsible usage of its medicines with HCPs 
through webinars and conferences. These sessions update HCPs on the science behind the medicines during 
Continuing Medical Education (CME) activities and webinars.
c. Dosage Instructions: Physicians direct the dosage instructions for prescriptive drugs based on their examination 
of patients. Product packaging clearly includes directives for usage under the guidance of a medical practitioner.
d. Comprehensive Product Information: Medical representatives use product information leaflets that include the 
generic name, composition, dosage form and strength, clinical particulars (e.g., therapeutic indication, method of 
administration), contraindications, special warnings and precautions on use, and overdose information.
e. Patient Education Materials: Posters and related materials are created for patient education in easy-to-understand 
language. These materials are also available in regional languages to ensure broader accessibility and understanding.
3.	
Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.
Keeping consumers informed about disruptions or discontinuations of essential services is crucial. Jagsonpal 
employs these methods to keep consumers informed. In addition to providing public announcements through 
newspapers and press releases, providing periodic updates on the company website, leveraging social media 
platforms, and providing a dedicated email address for customer queries.
4.	
Does the entity display product information on the product over and above what is mandated as per local 
laws? (Yes/No/ Not Applicable) If yes, provide details in brief. Did your entity carry out any survey with 
regard to consumer satisfaction relating to the major products/ services of the entity, significant locations 
of operation of the entity or the entity as a whole? (Yes/No)
The Company follows the regulations under the Drugs and Cosmetics Act and Rules with respect to product 
packaging. Anti-counterfeit features have also been incorporated on the packaging of some of our products. Other 
product information includes:
•	
QR code (in Divatrone), code numbers (Lycored softgels) and holographic strips on some of the products for 
verification of genuineness of products.
•	
Products contain prescribing information leaflets, for ready reference by the healthcare professional/consumer, 
as per the regulatory requirement
Jagsonpal Pharmaceuticals Limited | Annual Report 2023-24
90
